To investigate certain biochemical and molecular characteristics of mitochondria in patients with Leber hereditary optic neuropathy (LHON)-like optic neuropathies. METHODS. Patients who had LHON-like optic neuropathies in both eyes were selected from neuro-ophthalmology clinics. Evaluation included clinical examination, neuroimaging, and assessment of several mitochondrial parameters in the blood, including sequencing the entire mitochondrial (mt)DNA coding region, measuring relative mtDNA content, studying mitochondrial respiratory function in some patients, and sequencing the OPA1 and OPA3 genes. RESULTS. Thirty-five patients (21 men and 14 women; average age at onset 19.0 Ϯ 8.7 years) met inclusion and exclusion criteria for LHON-like optic neuropathies with median visual acuity approximately 20/200. Other hereditary retinopathies and optic neuropathies were unlikely because of inclusion and exclusion criteria, because ERGs were normal, and because no patient had pathogenic sequence changes in the OPA1 or OPA3 genes. Compared with control subjects, these patients had more potentially pathogenic nonsynonymous mtDNA changes, greater relative mtDNA content (P Ͻ 0.001), and less mitochondrial respiratory activity (P Ͻ 0.001). Only six patients (17%) had primary LHON mutations; however, even the 29 patients without primary LHON mutations had significant evidence of mitochondrial abnormalities. Mitochondrial haplogroup distribution was similar in patients and control subjects. CONCLUSIONS. Primary LHON mutations are less common in patients with LHON-like optic neuropathy selected from a clinical setting than in patients with LHON from multigenerational families. The results suggest that mitochondrial dysfunction plays a role in this type of optic neuropathy whether or not primary LHON mutations are present. This information has implications for diagnostic testing and for future investigations into mechanisms of disease. (Invest Ophthalmol Vis Sci. 2006; 47:4211-4220)
L eber hereditary optic neuropathy (LHON) is one of the most common hereditary optic neuropathies. It was initially recognized as a maternally inherited optic neuropathy causing roughly symmetric, subacute visual loss in young men 1 and was the first disease to be associated with a mitochondrial (mt)DNA mutation. 2 The mechanism by which mitochondrial abnormalities affect optic nerve viability and the reasons for the age of onset, incomplete penetrance, and male predominance all remain unknown.
The clinical characteristics of LHON overlap in part those of several other optic neuropathy phenotypes, and testing for the presence of primary LHON mutations (ND1/G3460A, ND4/ G11778A, and ND6/T14484C) has been helpful in making the diagnosis. Routine mtDNA screening usually covers only primary LHON mtDNA mutations because their prevalence is reported to be 90% or more in families with multigenerational visual loss. 3 However, some patients do not have any mtDNA nucleotide changes, 4 whereas other patients have potentially pathogenic mutations elsewhere in the mitochondrial genome. 5 Primary LHON mutations may be less common when patients with LHON-like optic neuropathies are selected from a clinic setting rather than from multigenerational families. 6 We investigated prospectively a series of patients presenting to neuro-ophthalmology clinics with bilateral simultaneous or sequential LHON-like optic neuropathies, to assess the frequency and severity of certain mitochondrial abnormalities in the blood. All patients were evaluated clinically and neuroradiologically. We studied the prevalence of primary LHON mutations and other mitochondrial abnormalities by sequencing the entire mtDNA coding region and assessing relative mtDNA content and mitochondrial respiration. Even though other hereditary optic neuropathies (e.g., dominant and recessive optic atrophy) and retinopathies cause chronic rather than acute or subacute visual loss, we also sequenced the OPA1 and OPA3 genes and performed electroretinograms (ERGs) to exclude these potential diagnoses.
METHODS

Patient Enrollment
Patients were enrolled from the neuro-ophthalmology clinics at the King Khaled Eye Specialist Hospital and the King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia, after obtaining informed consent approved by the appropriate institutional review board. This research adhered to the tenets of the Declaration of Helsinki.
Patients were eligible for inclusion if they reported acute or subacute visual loss in both eyes simultaneously or sequentially within 1 year, had clinical evidence of relatively symmetric optic neuropathies with central visual loss, and were of age less than 50 years at onset of visual symptoms. Exclusion criteria included exposure to a known optic nerve toxin; pain at onset or recovery of vision more compatible with optic neuritis; historical, neuroimaging, or biochemical evidence of multiple sclerosis or another systemic inflammatory disease; a cause of significant visual loss in either eye independent of optic neuropathy; substantial neurologic disease outside of the optic nerve; evidence on history, examination, or neuroimaging of an alternative medical, surgical, or syndromatic cause of optic neuropathy; or refusal to participate.
Neuroimaging was obtained on a CT or MRI scanner (Magnetom Allegra 3.0 Tesla MRI Scanner or Somatom Sensation 4 CT Scanner; Siemens, Madison, WI). Electroretinograms were performed on an evoked-potential system (Spirit; Nicolet Instrument Corp., Madison, WI), according to the manufacturer's suggested protocol. 
Control Subjects
Sample Collection and DNA Extractions
A single-density gradient (Ficoll-Paque-PLUS; Pharmacia Biotech AB, Uppsala, Sweden) was used for lymphocyte separation and isolation from peripheral blood, as detailed previously.
7 DNA was extracted from whole blood samples of all patients with LHON-like optic neuropathies and control subjects by using a DNA isolation kit (PureGene) from Gentra Systems (Minneapolis, MN).
DNA Amplification and Sequencing
The entire coding region of the mitochondrial genome was amplified in 24 separate polymerase chain reactions (PCRs) using single set cycling conditions, as detailed elsewhere, 8 for all patients and control subjects. Each successfully amplified fragment was directly sequenced with dye termination chemistry (BigDye Terminator ver. 3.1 Cycle Sequencing kit; Applied Biosystems, Inc.
[ABI], Foster City, CA), and samples were run on a sequencer (Prism 3100; ABI).
Sequence Analysis of the mtDNA Coding Region
Sequencing results were compared with the corrected Cambridge reference sequence. 5 All fragments were sequenced in both forward and reverse directions at least twice, for confirmation of a detected variant. Patient mtDNA sequences were compared with those from local control subjects, and all sequence variants were compared with the MITOMAP database, 5 the Human Mitochondrial Genome Database (http://www. genpat.uu.se/mtDB/ Uppsala University), GenBank (http://www.ncbi. nlm.nih.gov/GenBank/index.html/ NIH, Bethesda, MD), and Medline listed publications (NIH), all provided in the public domain.
Mitochondrial Haplogroup Analysis
After sequencing the entire mitochondrial DNA and establishing sequence changes for each patient and control, we performed mitochondrial haplogrouping based on the classifications detailed previously.
9,10
Prediction of Pathogenicity
Pathogenic characteristics of previously undescribed (novel) nonsynonymous mtDNA sequence changes were determined according to a combination of standard criteria 11 ; an evaluation of interspecies conservation using the Polyphen database (http://genetics.bwh.harvard-.edu/pph/ Brigham and Women's Hospital, Harvard Medical School, Boston, MA), and when necessary, the Mamit-tRNA Web site (http:// mamit-trna.u-strasbg.fr/index.html/ Institute of Molecular and Cellular Biology, Strasbourg, France), both sources provided in the public domain; analysis of predicted changes in the hydropathy index, as measured by a commercial software program (Protean program, part of the Lasergene ver 6 software; (DNAStar, Inc. Madison, WI), according to the Kyte-Doolittle method, which predicts the regional hydropathy of proteins from their amino acid sequence (values were assigned for all amino acids and then averaged over a window size of 7); assessment of the possible impact of an amino acid substitution on three-dimensional protein structure using Protean, which also predicts and displays secondary structural characteristics; and assessment of the possible effect of the mtDNA change on protein function using Polyphen 12 and the SIFT (Sorting Intolerant from Tolerant) program (http://blocks. fhcrc.org/sift/SIFT.html/ Fred Hutchinson Cancer Research Center, Seattle, WA), which predicts whether protein substitutions are tolerated. 13 Therefore, a novel nonsynonymous nucleotide change was considered potentially pathogenic if (1) it was not reported in mitochondrial databases or Medline-listed literature as a confirmed polymorphism; (2) it was not present in local control subjects; (3) it changed a moderately or highly conserved amino acid; (4) it occurred in a region of high interspecies conservation; (5) Protean predicted an alteration of protein structure; (6) it was assessed as possibly or probably pathogenic by PolyPhen; and (7) it was predicted by SIFT to have an effect on protein function. For previously reported nonsynonymous nucleotide changes, consideration was given to pathogenic status determined by others and by mitochondrial databases in addition to these criteria.
Quantification of Heteroplasmy
The heteroplasmy level was determined for each heteroplasmic sequence variant by the primer extension assay described previously. 14 Heteroplasmy level was quantified from fluorescence intensities associated with electrophoretically resolved mutant and wild-type peaks (GeneScan ver. 3.7; ABI). Percentage heteroplasmy was calculated using the following equation: [fluorescent band intensity for the mutant/(fluorescent band intensity for the wild-type ϩ fluorescent band intensity for the mutant)] ϫ 100.
Determination of Relative Mitochondrial DNA Content
Competitive multiplex PCR was performed with two simultaneous primer sets, as described previously. 15 One pair was designed to amplify a 450-bp fragment of the ND1 mitochondrial gene and the other pair to amplify a 315-bp fragment of the ␤-actin nuclear gene, which served as an internal control. Control samples were run simultaneously with those of patients. PCR products were separated on 1% agarose gel at 100 V for 1 hour, and the intensity of the two bands was quantified by the use of gel imager (Typhoon 9410; GE Healthcare, Schenectady, NY). The ratio of ND1 to ␤-actin was determined for each patient and control subject by dividing the fluorescence intensity of the ND1 band by the intensity of the ␤-actin band.
Measurement of Mitochondrial Functional Testing
Resazurin is a redox-active blue dye that becomes pink and highly fluorescent when reduced. It competes with oxygen for electrons in a standard preparation of circulating lymphocytes, and a change in fluorescence (corrected for background and protein concentration) reflects respiration. Lymphocytes from 19 patients and 62 control subjects were incubated with 6 M resazurin, without and with mitochondrial inhibition by amiodarone 200 M, and the fluorescence intensity resulting from resazurin reduction was monitored spectrofluorimetrically over time. Mitochondrial respiratory activity (MRA) was calculated as the difference between uninhibited and inhibited measurements at 240 minutes, taken in triplicate, averaged, and normalized for protein concentration and background activity, as described previously. 
Sequence Analysis of OPA1 and OPA3 Genes
The 31 coding exons, exon-intron boundaries, and promoter regions of the OPA1 gene were amplified by PCR from genomic DNA for all patients and subjected to direct sequencing, as described previously. 16 Similarly, the whole coding region and exon-intron boundaries for the OPA3 gene were sequenced in all patients by using a protocol described previously.
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Statistical Methods
All statistical analyses were performed with commercial software (SPSS for Windows ver 13.0; SPSS Inc, Chicago, IL). Snellen visual acuities were converted to ordinal values, and color vision was quantified on an equalinterval scale as the number of Ishihara color plates identified (of 10) with 20/200 . Visual acuity correlated positively and significantly between the two eyes (r ϭ 0.74; P Ͻ 0.001) and with color vision (r ϭ 0.62 OD and 0.58 OS; P Ͻ 0.001 for either eye), but correlated negatively with age at onset (r ϭ Ϫ0.263; P ϭ 0.028) and did not correlate with sex. All patients had normal erythrocyte sedimentation rates, antinuclear antibodies, and syphilis serology. Three patients (patients 19, 21, and 23) had vitamin B12 levels slightly below the normal range without anemia, megaloblastic changes, other neurologic signs or symptoms, or neuroimaging abnormalities.
RESULTS
Clinical Description
Thirty patients had remote visual loss and optic atrophy OU at presentation, whereas five (patients 3, 5, 6, 7, and 35) had swelling of the papillary and peripapillary nerve fiber layer around the time of visual loss that evolved to optic atrophy (Fig. 1) . 1, 18 Patient 14 experienced substantial recovery of visual acuity OU with doughnut scotomas typical of recovering LHON 19, 20 documented in several examinations over 10 months (Fig. 2) .
All patients had brain neuroimaging, including magnetic resonance imaging in 27 and computed tomography in 18. No scan revealed a mass or an alternative cause of optic neuropathy such as evidence of demyelination. Optic nerves and/or optic chiasm appeared relatively small in 11 patients. Twentytwo patients received electroretinograms, all which had waveforms within the institutional normal range for latency and amplitude. Table 2 displays the 41 nonsynonymous (resulting in amino acid change) mtDNA sequence variants detected in patients. Supplementary Table S1, online at http://www.iovs.org/cgi/ content/full/47/10/4211/DC1, presents additional detail regarding predicted changes in the hydropathy index, protein structure, and protein function supporting pathogenicity analyses for the nonsynonymous sequence changes listed in Table  2 . Table 3 .
Sequence Analysis of the Mitochondrial DNA Coding Region
Of the nonsynonymous sequence changes listed in Table 2 , 21 (51.3%) were in complex I, 7 (17.1%) in complex III, 5 (12.2%) in complex IV, 6 (14.6%) in complex V, 1 (2.4%) in tRNA glutamine , and 1 (2.4%) in 12S rRNA. These mtDNA changes were predominantly transitions rather than transversions, similar to the definite and provisional mtDNA changes previously reported in association with LHON. 5 Five nucleotide changes were heteroplasmic (nt 4040, 7369, 10543, 10591, and 12782), and heteroplasmy levels were near the typical mutation load threshold for pathogenic mtDNA mutations (Ն60%) 21, 22 for three. Both nt 4040 and 7369 were heteroplasmic in control subjects (range, 18% to 25%), but all other sequences in control subjects were homoplasmic.
Primary LHON mutations nt 3460 and 11778 were found in patients 1 to 6, but nt 14484 was not represented. No primary LHON mutation was found in control subjects. All four secondary LHON mutations (nt 4216, 4917, 13708, and 15257) were present in patients and in control subjects in comparable frequencies. One provisional LHON mutation (nt 10663) 23 was detected in two patients (patients 29 and 35), and two previously reported somatic mutations (nt 6261 24 and 10591 25 ) were present in one patient each (patients 28 and 25, respectively). These three mtDNA mutations were not present in control subjects. Sixteen other recognized nonsynonymous mtDNA polymorphisms were detected in both patients and control subjects in comparable frequencies (see Table 2 ). Nine novel (unreported elsewhere as a mutation or polymorphism to date) homoplasmic nonsynonymous nucleotide changes were identified in patients but not control subjects. Fourteen sequence changes (including nt 11778, 3460, 10663, 6261, 10591, and nine novel mtDNA changes) were considered probably pathogenic.
Age at onset of symptoms, color vision (CV), and frequency of consanguinity did not differ significantly between patients with primary LHON mutations (patients 1-6) and other patients (patients 7-35). However, mean VA of the six patients with primary LHON mutations (slightly Ͻ20/400) was significantly worse than that of the 29 patients without primary mutations (slightly better than 20/200; 2 P ϭ 0.009). All patients with primary LHON mutations were men, whereas women comprised half (14/29) of patients without LHON mutations. Table 3 also lists relative mtDNA content for each patient, and Table 4 compares these results with those in control subjects. The mean relative mtDNA content was significantly greater in all patients and in patients without primary LHON mutations than in control subjects (P Ͻ 0.001 for both comparisons). The optimal relative mtDNA content level to distinguish between control subjects and all patients was 1.76 as calculated by ROC curve (not shown; area under ROC curve 0.77; 95% CI, 0.65-0.89), and 24 patients had relative mtDNA content greater than this value. Relative mtDNA content did not correlate with clinical characteristics (age at onset, sex, VA, or CV) and was not different between patients with pathogenic or potentially pathogenic mtDNA changes and other patients. Table 3 also lists MRA values for each patient, and Table 4 compares these results to control subjects. Mean MRA in all studied patients (n ϭ 19) and in patients without primary LHON mutations (n ϭ 14) was significantly less than in control 
Relative Mitochondrial DNA Content
Mitochondrial Functional Testing
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Mitochondrial Haplogroup Analysis
Sequence Analysis of OPA1 and OPA3 Genes
There were no polymorphisms, previously recognized mutations, or sequence variants detected in the coding exons, exon-intron boundaries, or the promoter region of the OPA1 or OPA3 genes in these patients. These genes were nonpolymorphic in this patient group.
DISCUSSION
We enrolled 35 patients from clinic who experienced acute or subacute, bilateral, persistent optic neuropathies characterized by central visual loss that occurred simultaneously or sequentially within 1 year. Diagnostic criteria were designed to exclude individuals with toxic optic nerve injury, optic nerve compression, systemic disease, optic neuritis, and nonarteritic ischemic optic neuropathy (NAION). Hereditary retinopathies and other hereditary optic neuropathies were unlikely because patients reported subacute rather than chronic visual loss in both eyes, because ERGs were normal, and because sequencing OPA1 and OPA3 yielded no mutations. The haplogroup spectrum of patients mirrored that of control subjects. Haplogroup J1 may act as a background risk factor for disease expression in patients with nt 11778 and with the provisional LHON mutation nt 10663, as previously suggested. 22, 23 These patients also had other clinical characteristics reminiscent of LHON, 1 including moderately severe optic nerve disease with central visual field loss beginning around age 19 and with a strong correlation between VA in the two eyes. However, only six patients had primary LHON mutations. These six had additional similarities to patients in previous LHON studies, including preponderance of males, peripapillary telangiectasias and pseudoedema of the optic disc, predominance of the nt 11778 mutation with haplogroup J1 background, and significantly increased relative mtDNA content. 26 Mitochondrial respiration was significantly reduced, in agreement with previous studies of mitochondrial function in LHON patients that documented decreased activity of certain mitochondrial enzymes, 27 impaired complex I respiration, 28 and increased sensitivity to complex I inhibitors. 29 Nevertheless, none of the patients with primary LHON mutations reported a multigenerational history compatible with maternal inheritance.
Even patients without primary LHON mutations had more probably pathogenic mtDNA nucleotide changes, significantly greater relative DNA content, and significantly lower MRA than control subjects. These patients were clinically similar to patients with primary LHON mutations, except that half were women. With or without primary mutations, it seems likely that mitochondrial disturbances contribute to the vulnerability of the optic nerve to this type of injury by mechanisms not yet completely understood and possibly in concert with other factors not yet recognized. 30 The concentration of mitochondria at the optic nerve head implies dependency on some aspect of mitochondrial function, 31 and mitochondria-induced apoptosis may be a final mechanism of optic nerve injury in all patients with LHON-like optic neuropathies. 32, 33 Some of these patients had mtDNA changes predicted to be pathogenic, whereas others had no suspicious mtDNA changes. Patients with no obvious mtDNA abnormalities might have no mitochondrial disease, or they might have mtDNA abnormalities isolated to the optic nerve, conceptually similar to mitochondrial myopathies. 34 However, taken together, these patients had elevated relative mtDNA content and reduced MRA in blood, suggesting systemic oxidative stress comparable to patients with primary LHON mutations. 35 Previous studies have described similar patients with LHON-like optic neuropathies but no identified pathogenic mtDNA mutations after sequencing all 4 or part 6,36 of the mitochondrial coding region. In this setting, unidentified nuclear 37, 38 and/or environmental 39, 40 factors affecting mitochondrial function may be risk factors for LHON-like optic nerve damage.
The prevalence of primary LHON mutations in this series of patients with LHON-like optic neuropathies is substantially less than the 90% figure frequently mentioned for patients with LHON 1 that derives largely from studies of multigenerational families. 3 In fact, these results may be typical of a clinical setting. In another series of 32 individuals with LHON-like optic neuropathies enrolled from a clinic, rather than from multigenerational families, there were primary LHON mutations in only 5 (16%) patients. 6 In addition, a large commercial laboratory identified primary LHON mutations in only 11.4% of submitted samples (343/3000 samples had nt 11778, 3460, or 14484; Athena Diagnostics, Inc., Worcester, MA, personal communication, February 2006). These data and the information presented herein suggest that fewer than one in five patients with LHON-like optic neuropathies selected from doctors' offices have primary LHON mutations and that most do not describe a recognizable family history. * Listed are nonsynonymous mtDNA nucleotide changes that are known to be pathogenic (e.g., primary LHON mutations), are possibly pathogenic (e.g., secondary LHON mutation, provisional LHON mutations, or somatic mutations), or are novel in this patient series. Nonsynonymous polymorphisms and nonsynonymous mtDNA changes important to haplogroup designation with no pathogenic significance are listed in Supplementary Table S2 http://www.iovs.org/cgi/content/full/47/10/4211/DC1. Underscored nucleotide changes are known or suspected to be pathogenic (see Table 2 and Supplementary Table S1 http://www.iovs.org/cgi/content/full/47/10/4211/DC1).
† Haplogrouping was based on previously established haplogroup specific polymorphisms. 9 "Other" signifies that mitochondrial haplogroup could not be assigned unambiguously to one of the major known haplogroups based on the sequence changes detected. Patients 20 and 21 could not be grouped beyond M1.
‡ The optimal values to distinguish between controls and patients were Ͼ1.76 for relative mtDNA content.
§ The optimal values to distinguish between controls and patients were Ͻ21.2 for MRA. 18 and a doughnut scotoma during recovery 20 are strongly linked to LHON, but were present in our study in patients without a primary LHON mutation or a maternal inheritance pattern. The clinical characteristics of LHON and its association with primary LHON mutations are well recognized. This report identifies similar clinical characteristics in patients with LHON-like optic neuropathies who do not have a maternal family history and associates these characteristics with a broader spectrum of mitochondrial abnormalities.
We report a fairly small group of patients from a restricted ethnic population, and this type of evaluation should be repeated in other centers. If these results are confirmed, the demographic importance of LHON-like optic neuropathies has been substantially underestimated. Extrapolating from data regarding primary LHON mutations, the prevalence of visual loss from mitochondria-associated LHON-like optic neuropathies might approach 20 per 100,000 individuals, 43 and this diagnosis may be responsible for as much as 10% of blindness in individuals under age 65. 44 Given this possibility, sequencing the entire mitochondrial genome and measuring relative mitochondrial content may be warranted when patients with LHON-like optic neuropathies do not have primary LHON mutations. Resazurin testing of mitochondrial respiratory activity is also a simple, reproducible procedure that can add an in vivo functional assessment to the evaluation of patients with LHON-like optic neuropathies and other mitochondrial syndromes. 
